Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity (2018 - 2021)
Historic Liabilities and Shareholders Equity for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $274.1 million.
- Black Diamond Therapeutics' Liabilities and Shareholders Equity fell 2087.23% to $274.1 million in Q3 2021 from the same period last year, while for Dec 2021 it was $875.3 million, marking a year-over-year decrease of 3695.67%. This contributed to the annual value of $329.7 million for FY2020, which is 10826.31% up from last year.
- Latest data reveals that Black Diamond Therapeutics reported Liabilities and Shareholders Equity of $274.1 million as of Q3 2021, which was down 2087.23% from $287.9 million recorded in Q2 2021.
- Black Diamond Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $362.8 million during Q1 2020, with a 5-year trough of $51.8 million in Q4 2018.
- Moreover, its 4-year median value for Liabilities and Shareholders Equity was $313.3 million (2021), whereas its average is $274.9 million.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 20543.55% in 2019, then tumbled by 2087.23% in 2021.
- Quarter analysis of 4 years shows Black Diamond Therapeutics' Liabilities and Shareholders Equity stood at $51.8 million in 2018, then soared by 205.44% to $158.3 million in 2019, then surged by 108.26% to $329.7 million in 2020, then decreased by 16.85% to $274.1 million in 2021.
- Its Liabilities and Shareholders Equity stands at $274.1 million for Q3 2021, versus $287.9 million for Q2 2021 and $313.3 million for Q1 2021.